Matches in Nanopublications for { ?s ?p ?o <http://www.tkuhn.ch/bel2nanopub/RAhhdhMJ1ZWfk6LnTsCCo_FQnqqpvYCPqW9jNdABVfc1M#provenance>. }
Showing items 1 to 11 of
11
with 100 items per page.
- _7 label "Selventa" provenance.
- large_corpus.bel title "BEL Framework Large Corpus Document" provenance.
- large_corpus.bel description "Approximately 61,000 statements." provenance.
- large_corpus.bel version "1.4" provenance.
- large_corpus.bel authoredBy _7 provenance.
- assertion wasDerivedFrom large_corpus.bel provenance.
- assertion wasDerivedFrom _6 provenance.
- assertion hadPrimarySource 17554333 provenance.
- _6 wasQuotedFrom 17554333 provenance.
- _6 value "show a good clinical response to EGFR TKIs such as gefitinib, but they almost invariably develop drug resistance after an average of 12 months5. A secondary mutation in exon 20 (T790M) is found in about half of patients with a primary mutation that have grown resistant after an initial response to EGFR TKIs6–8. More recently, a new secondary mutation (D761Y) was found in a brain metastasis of a lung cancer initially responsive to gefitinib9. So far, T790M and D761Y are the only acquired alterations identified in the EGFR associated with escape from TKI therapy." provenance.
- large_corpus.bel rights "Copyright (c) 2011-2012, Selventa. All rights reserved." provenance.